Progression to cancer in patients with confirmed dysplasia compared to dysplasia downgraded to non-dysplastic metaplasia in Barrett’s esophagus: a retrospective cohort study in Sweden

키워드

참고문헌 (21)

1. Lagergren J, "Symptomatic gastro esophageal reflux as a risk factor for esophageal adenocarcinoma", N Engl J Med, 340, pp.825~831 (1999)
2. Chen YH, "Prevalence and risk factors for Barrett's esophagus in Taiwan", World J Gastroenterol, 25, pp.32313241~ (2019)
3. Morgan E, "The global landscape of esophageal squamous cell carcinoma and esophageal adenocarci noma incidence and mortality in 2020 and projections to 2040 : new estimates from GLOBOCAN 2020", Gastroenterology, 163, pp.649658~ (2022)
4. Kastelein F, "Impact of sur veillance for Barrett's oesophagus on tumour stage and survival of patients with neoplastic progression", Gut, 65, pp.548~554 (2016)
5. Weusten B, "Endoscopic management of Barrett's esophagus : European Society of Gastrointestinal Endoscopy(ESGE)Position Statement", Endoscopy, 49, pp.191~198 (2017)
6. Fitzgerald RC, "British Society of Gastroenterology guidelines on the diagnosis and management of Barrett's oesophagus", Gut, 63, pp.7~42 (2014)
7. ASGE Standards of Practice Committee, "ASGE guideline on screening and surveillance of Barrett's esopha gus", Gastrointest Endosc, 90, pp.335~359 (2019)
8. Shaheen NJ, "ACG clinical guideline : diag nosis and management of Barrett's esophagus", Am J Gastroenterol, 111, pp.30~50 (2016)
9. Sharma P, "AGA clinical practice update on endoscopic treatment of Barrett’s esophagus with dysplasia and", or early cancer : expert review, 2020, pp.158, 760~769
10. Duits LC, "Barrett's oesophagus patients with low-grade dysplasia can be accurately risk-stratified after histo logical review by an expert pathology panel", Gut, 64, pp.700~706 (2015)
11. Phoa KN, "Radiofrequency ablation vs endoscopic surveillance for patients with Barrett esoph agus and low-grade dysplasia : a randomized clinical trial", JAMA, 311, pp.1209~1217 (2014)
12. Marques de Sá I, "Systematic review of the published guidelines on Barrett's esophagus : should we stress the consensus or the differences", Dis Esophagus (2020)[DOI]
13. Côté RA, "Progress in medical information manage ment. Systematized nomenclature of medicine(SNOMED)", JAMA, 243, pp.756~762 (1980)
14. Schlemper RJ, "The Vienna classification of gastrointestinal epithelial neoplasia", Gut, 47, pp.251~255 (2000)
15. Skacel M, "The diagnosis of low-grade dysplasia in Barrett's esophagus and its implications for disease pro gression", Am J Gastroenterol, 95, pp.3383~3387 (2000)
16. Januszewicz W, "The utility of P53 im munohistochemistry in the diagnosis of Barrett's oesophagus with indefinite for dysplasia", Histopathology, 80, pp.1081~1090 (2022)
17. Krishnamoorthi R, "Risk of progression in Barrett's esophagus indefinite for dysplasia : a systematic review and meta-analysis", Gastrointest Endosc, 91, pp.3~10 (2020)
18. Frei NF, "Risk stratification in Barrett’s esophagus patients with diagnoses of indefinite for dysplasia : the definite silver bullet has not(yet)been found", Gastrointest Endosc, 91, pp.11~13 (2020)
19. Pohl H, "Length of Barrett's oesophagus and cancer risk : implications from a large sample of patients with early oesophageal adenocarcinoma", Gut, 65, pp.196~201 (2016)
20. Ekheden I, "Esophageal abnormalities and the risk for gastroesophageal cancers-a histopathology-regis ter-based study in Sweden", Eur J Epidemiol, 37, pp.401~411 (2022)
21. Elbe P, "Ablation of Barrett esopha gus. Treatment modalities under development", Lakartidningen, 110, pp.624~626 (2013)

관련 논문AI추천